[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.232.99. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1974

Horizons in Tumor ImmunologyA Seminar

Author Affiliations

Boston; Surrey, England; Boston; Minneapolis
From the Chester Beatty Research Institute, Royal Cancer Hospital, Surrey, England (Prof Alexander); Peter Bent Brigham Hospital and Harvard Medical School, Boston (Drs. Rosenberg and Wilson); and University of Minnesota Medical School, Minneapolis (Dr. Simmons).

Arch Surg. 1974;109(1):17-29. doi:10.1001/archsurg.1974.01360010009003
Abstract

Dr. Wilson: Although we really have to thank the Gordon Conference for attracting two of our three speakers to Boston this morning, we are pleased to have them under any circumstances because we are excited about this seminar. I have entitled the seminar "Horizons in Tumor Immunology" because I hope the speakers will be presenting a synthesis of new ideas rather than any large series of treated patients.

Immunotherapy is not really a new concept, but lately it has gained perspective and prominence. Contributing to this increase in interest has been the growing sophistication of investigations on many fronts and many disciplines; evidence of our capability to perform immune manipulation, particularly in the field of transplantation; and, finally, the realization that more aggressive surgery does not necessarily produce higher cure rates in cancer. Immunotherapy offers the chance to destroy the last remaining tumor cell. Our approach here at the Peter

First Page Preview View Large
First page PDF preview
First page PDF preview
×